当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2017-11-01 , DOI: 10.1016/s2213-8587(17)30323-6
Rosario Pivonello , Carolina Di Somma , Annamaria Colao

First page of articleThe most common complication in people who are born small for gestational age is persistent short stature: approximately 10% of children born small for gestational age will remain less than 2 SDs for height throughout childhood and adulthood. As a result, such children who do not have suitable catch-up growth during the first years of life and who are growing at an average or below average rate are candidates for treatment with recombinant growth hormone.1 Being born small for gestational age is also associated with an increased risk of cardiometabolic disorders in adulthood, including diabetes, dyslipidaemia, and cardiovascular disease.

中文翻译:

胎龄较小的人停止生长激素治疗后的心血管风险

文章首页在胎龄小的人中最常见的并发症是持续的矮小身材:在胎龄小的儿童中,大约10%的儿童在整个童年和成年时期的身高保持低于2 SD。结果,这样的儿童在生命的最初几年中没有适当的追赶性生长,并且以平均或低于平均水平的速度生长,因此是用重组生长激素治疗的候选者。1胎龄小还与成年期心脏代谢异常风险增加有关,包括糖尿病,血脂异常和心血管疾病。
更新日期:2017-11-22
down
wechat
bug